| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
Surgery Branch, National Cancer Institute, Bethesda, MD 20892
Neoantigens resulting from the inherent genomic instability of tumor cells generally do not trigger immune recognition. Similarly, transfection of tumors with model Ags often fails to elicit CD8+ T cell responses or alter a tumor’s growth rate or lethality. We report here that the adoptive transfer of activated Th1-type CD4+ T cells specific for a model tumor Ag results in the de novo generation of CD8+ T cells with specificity to that Ag and concomitant tumor destruction. The anti-tumor effects of the CD4+ T cells required the presence of both MHC class I and class II on host cells, as evidenced by experiments in knockout mice, suggesting that CD4+ T cells enhanced the ability of host APC to activate endogenous CD8+ T cells. These results indicate that the apparent inability of tumor cells expressing highly immunogenic epitopes to activate tumor-specific CD8+ T cells can be altered by activated CD4+ T cells.
This article has been cited by other articles:
|
|
 |
|
  Z. Liu, H. S. Noh, J. Chen, J. H. Kim, L. D. Falo Jr., and Z. You Potent Tumor-Specific Protection Ignited by Adoptively Transferred CD4+ T Cells J. Immunol., September 15, 2008; 181(6): 4363 - 4370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Kalli, C. J. Krco, L. C. Hartmann, K. Goodman, M. J. Maurer, C. Yu, E. M. Johnson, C. L. Erskine, M. L. Disis, P. J. Wettstein, et al. An HLA-DR-Degenerate Epitope Pool Detects Insulin-like Growth Factor Binding Protein 2-Specific Immunity in Patients with Cancer Cancer Res., June 15, 2008; 68(12): 4893 - 4901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Vujanovic, M. Mandic, W. C. Olson, J. M. Kirkwood, and W. J. Storkus A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6 Clin. Cancer Res., November 15, 2007; 13(22): 6796 - 6806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Paulos, A. Kaiser, C. Wrzesinski, C. S. Hinrichs, L. Cassard, A. Boni, P. Muranski, L. Sanchez-Perez, D. C. Palmer, Z. Yu, et al. Toll-like Receptors in Tumor Immunotherapy Clin. Cancer Res., September 15, 2007; 13(18): 5280 - 5289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Willemsen, Z. Sebestyen, C. Ronteltap, C. Berrevoets, J. Drexhage, and R. Debets CD8{alpha} Coreceptor to Improve TCR Gene Transfer to Treat Melanoma: Down-Regulation of Tumor-Specific Production of IL-4, IL-5, and IL-10 J. Immunol., July 15, 2006; 177(2): 991 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Lepage and R. Lapointe Melanosomal Targeting Sequences from gp100 Are Essential for MHC Class II-Restricted Endogenous Epitope Presentation and Mobilization to Endosomal Compartments Cancer Res., February 15, 2006; 66(4): 2423 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tanaka, S. Koido, J. Xia, M. Ohana, C. Liu, G. M. Cote, D. B. Sawyer, S. Calderwood, and J. Gong Development of Antigen-Specific CD8+ CTL in MHC Class I-Deficient Mice through CD4 to CD8 Conversion J. Immunol., June 15, 2004; 172(12): 7848 - 7858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. K. Dissanayake, J. A. Thompson, J. J. Bosch, V. K. Clements, P. W. Chen, B. R. Ksander, and S. Ostrand-Rosenberg Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell Vaccines: A Novel Cell-based Immunotherapy Cancer Res., March 1, 2004; 64(5): 1867 - 1874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Cuenca, F. Cheng, H. Wang, J. Brayer, P. Horna, L. Gu, H. Bien, I. M. Borrello, H. I. Levitsky, and E. M. Sotomayor Extra-Lymphatic Solid Tumor Growth Is Not Immunologically Ignored and Results in Early Induction of Antigen-Specific T-Cell Anergy: Dominant Role of Cross-Tolerance to Tumor Antigens Cancer Res., December 15, 2003; 63(24): 9007 - 9015. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Haicheur, F. Benchetrit, M. Amessou, C. Leclerc, T. Falguieres, C. Fayolle, E. Bismuth, W. H. Fridman, L. Johannes, and E. Tartour The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization Int. Immunol., October 1, 2003; 15(10): 1161 - 1171. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Orsini, R. Bellucci, E. P. Alyea, R. Schlossman, C. Canning, S. McLaughlin, P. Ghia, K. C. Anderson, and J. Ritz Expansion of Tumor-specific CD8+ T Cell Clones in Patients with Relapsed Myeloma after Donor Lymphocyte Infusion Cancer Res., May 15, 2003; 63(10): 2561 - 2568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Parkhurst, C. DePan, J. P. Riley, S. A. Rosenberg, and S. Shu Hybrids of Dendritic Cells and Tumor Cells Generated by Electrofusion Simultaneously Present Immunodominant Epitopes from Multiple Human Tumor-Associated Antigens in the Context of MHC Class I and Class II Molecules J. Immunol., May 15, 2003; 170(10): 5317 - 5325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Tutt, L. O'Brien, A. Hussain, G. R. Crowther, R. R. French, and M. J. Glennie T Cell Immunity to Lymphoma Following Treatment with Anti-CD40 Monoclonal Antibody J. Immunol., March 15, 2002; 168(6): 2720 - 2728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Lapointe, R. E. Royal, M. E. Reeves, I. Altomare, P. F. Robbins, and P. Hwu Retrovirally Transduced Human Dendritic Cells Can Generate T Cells Recognizing Multiple MHC Class I and Class II Epitopes from the Melanoma Antigen Glycoprotein 100 J. Immunol., October 15, 2001; 167(8): 4758 - 4764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kobayashi, J. Lu, and E. Celis Identification of Helper T-Cell Epitopes That Encompass or Lie Proximal to Cytotoxic T-Cell Epitopes in the gp100 Melanoma Tumor Antigen Cancer Res., October 1, 2001; 61(20): 7577 - 7584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Toungouz, M. Libin, F. Bulte, L. Faid, F. Lehmann, D. Duriau, M. Laporte, D. Gangji, C. Bruyns, M. Lambermont, et al. Transient expansion of peptide-specific lymphocytes producing IFN-{gamma} after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors J. Leukoc. Biol., June 1, 2001; 69(6): 937 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Fallarino, U. Grohmann, R. Bianchi, C. Vacca, M. C. Fioretti, and P. Puccetti Th1 and Th2 Cell Clones to a Poorly Immunogenic Tumor Antigen Initiate CD8+ T Cell-Dependent Tumor Eradication In Vivo J. Immunol., November 15, 2000; 165(10): 5495 - 5501. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Peng, J. Kjaergaard, G. E. Plautz, D. E. Weng, S. Shu, and P. A. Cohen Helper-Independent, L-Selectinlow CD8+ T Cells with Broad Anti-Tumor Efficacy Are Naturally Sensitized During Tumor Progression J. Immunol., November 15, 2000; 165(10): 5738 - 5749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Touloukian, W. W. Leitner, S. L. Topalian, Y. F. Li, P. F. Robbins, S. A. Rosenberg, and N. P. Restifo Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice J. Immunol., April 1, 2000; 164(7): 3535 - 3542. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
